The US Food and Drug Administration has granted approval to Nubeqa (darolutamide), a non-steroidal androgen receptor inhibitor developed by Finnish drugmaker Orion (Nasdaq: OMX).
Development partner Bayer (BAYN: DE) has submitted for approval in Europe and in Japan.
The approval covers non-metastatic castration-resistant prostate cancer (nmCRPC), in combination with androgen deprivation therapy (ADT).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze